A phase II trial of m-AMSA in patients with small-cell lung cancer.

R. B. Natale, Richard J. Gralla, R. E. Wittes

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.

Original languageEnglish (US)
Pages (from-to)393-395
Number of pages3
JournalCancer Clinical Trials
Volume4
Issue number4
StatePublished - Dec 1981
Externally publishedYes

Fingerprint

Amsacrine
Small Cell Lung Carcinoma
Appointments and Schedules
Therapeutics
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Natale, R. B., Gralla, R. J., & Wittes, R. E. (1981). A phase II trial of m-AMSA in patients with small-cell lung cancer. Cancer Clinical Trials, 4(4), 393-395.

A phase II trial of m-AMSA in patients with small-cell lung cancer. / Natale, R. B.; Gralla, Richard J.; Wittes, R. E.

In: Cancer Clinical Trials, Vol. 4, No. 4, 12.1981, p. 393-395.

Research output: Contribution to journalArticle

Natale, RB, Gralla, RJ & Wittes, RE 1981, 'A phase II trial of m-AMSA in patients with small-cell lung cancer.', Cancer Clinical Trials, vol. 4, no. 4, pp. 393-395.
Natale, R. B. ; Gralla, Richard J. ; Wittes, R. E. / A phase II trial of m-AMSA in patients with small-cell lung cancer. In: Cancer Clinical Trials. 1981 ; Vol. 4, No. 4. pp. 393-395.
@article{9c0904a8efbd44b69b654e1983275db9,
title = "A phase II trial of m-AMSA in patients with small-cell lung cancer.",
abstract = "Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.",
author = "Natale, {R. B.} and Gralla, {Richard J.} and Wittes, {R. E.}",
year = "1981",
month = "12",
language = "English (US)",
volume = "4",
pages = "393--395",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A phase II trial of m-AMSA in patients with small-cell lung cancer.

AU - Natale, R. B.

AU - Gralla, Richard J.

AU - Wittes, R. E.

PY - 1981/12

Y1 - 1981/12

N2 - Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.

AB - Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.

UR - http://www.scopus.com/inward/record.url?scp=0019751477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019751477&partnerID=8YFLogxK

M3 - Article

C2 - 6274533

AN - SCOPUS:0019751477

VL - 4

SP - 393

EP - 395

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -